The range of minimum provoking doses in hazelnut-allergic patients as determined by double-blind, placebo-controlled food challenges

被引:76
|
作者
Wensing, M
Penninks, AH
Hefle, SL
Akkerdaas, JH
van Ree, R
Koppelman, SJ
Bruijnzeel-Koomen, CAFM
Knulst, AC
机构
[1] Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3584 CX Utrecht, Netherlands
[2] TNO, Nutr & Food Res Inst, NL-3700 AJ Zeist, Netherlands
[3] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA
[4] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands
来源
CLINICAL AND EXPERIMENTAL ALLERGY | 2002年 / 32卷 / 12期
关键词
double-blind placebo-controlled food challenge; food allergy; hazelnut allergy; minimum provoking dose; threshold dose;
D O I
10.1046/j.1365-2222.2002.01555.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background The risk for allergic reactions depends on the sensitivity of individuals and the quantities of offending food ingested. The sensitivity varies among allergic individuals, as does the threshold dose of a food allergen capable of inducing an allergic reaction. Objective This study aimed at determining the distribution of minimum provoking doses of hazelnut in a hazelnut-allergic population. Methods Thirty-one patients with a history of hazelnut-related allergic symptoms, a positive skin prick test to hazelnut and/or an elevated specific IgE level, were included. Double-blind, placebo-controlled food challenges (DBPCFC) were performed with seven increasing doses of dried hazelnut (1 mg to 1 g hazelnut protein) randomly interspersed with seven placebo doses. Results Twenty-nine patients had a positive challenge. Itching of the oral cavity and/or lips was the first symptom in all cases. Additional gastrointestinal symptoms were reported in five patients and difficulty in swallowing in one patient. Lip swelling was observed in two patients, followed by generalized urticaria in one of these. Threshold doses for eliciting subjective reactions varied from a dose of 1 mg up to 100 mg hazelnut protein (equivalent to 6.4-640 mg hazelnut meal). Extrapolation of the dose-response curve showed that 50% of our hazelnut-allergic population will suffer from an allergic reaction after ingestion of 6 mg (95% CI, 2-11 mg) of hazelnut protein. Objective symptoms were observed in two patients after 1 and 1000 mg, respectively. Conclusion DBPCFCs demonstrated threshold doses in half of the hazelnut-allergic patients similar to doses previously described to be hidden in consumer products. This stresses the need for careful labelling and strategies to prevent and detect contamination of food products with hazelnut residues.
引用
收藏
页码:1757 / 1762
页数:6
相关论文
共 50 条
  • [41] DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF BULIMIC PATIENTS
    ROSEBUSH, P
    AMERICAN JOURNAL OF PSYCHIATRY, 1986, 143 (09): : 1197 - 1198
  • [42] Comparison of open and double-blind placebo-controlled food challenges in diagnosis of food hypersensitivity amongst children
    Venter, C.
    Pereira, B.
    Voigt, K.
    Grundy, J.
    Clayton, C. B.
    Gant, C.
    Higgins, B.
    Dean, T.
    JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2007, 20 (06) : 565 - 579
  • [43] Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial
    Gauvreau, Gail M.
    Sehmi, Roma
    Fitzgerald, J. Mark
    Leigh, Richard
    Cockcroft, Donald W.
    Davis, Beth E.
    Mayers, Irvin
    Boulet, Louis-Philippe
    Al-Sajee, Dhuha
    Salter, Brittany M.
    Cusack, Ruth P.
    Ho, Terence
    Whetstone, Christiane E.
    Alsaji, Nadia
    Satia, Imran
    Killian, Kieran J.
    Mitchell, Patrick D.
    Magee, Iain P.
    Bergeron, Celine
    Bhutani, Mohit
    Werkstrom, Viktoria
    Durzynski, Tomasz
    Shoemaker, Kathryn
    Katial, Rohit K.
    Jison, Maria
    Newbold, Paul
    Mccrae, Christopher
    O'byrne, Paul M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (03)
  • [44] PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS
    KENT, GG
    LANCET, 1980, 1 (8182): : 1363 - 1364
  • [45] False Positive Placebo Reaction in a Double-Blind Placebo-Controlled Food Challenge
    Reig Rincon de Arellano, I.
    Vazquez-Cortes, S.
    Sinaniotis, A. C.
    Fernandez-Rivas, M.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2009, 19 (03) : 241 - 242
  • [46] Outcome and safety of double-blind, placebo-controlled food challenges in 111 patients sensitized to lipid transfer proteins
    Gonzalez-Mancebo, Eloina
    Fernandez-Rivas, Montserrat
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (06) : 1507 - 1508
  • [47] Reintroduction failure is common among adolescents after double-blind placebo-controlled food challenges
    Strinnholm, A.
    Winberg, A.
    Hedman, L.
    Ronmark, E.
    Lindh, V.
    ACTA PAEDIATRICA, 2017, 106 (02) : 282 - 287
  • [48] New validated recipes for double-blind placebo-controlled low-dose food challenges
    Winberg, Anna
    Nordstrom, Lisbeth
    Strinnholm, Asa
    Nylander, Annica
    Jonsall, Anette
    Ronmark, Eva
    West, Christina E.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2013, 24 (03) : 282 - 287
  • [49] To face fear: a qualitative study of adolescents' experiences of double-blind, placebo-controlled food challenges
    Strinnholm, A.
    Winberg, A.
    Hedman, L.
    Ronmark, E.
    Lindh, V
    ALLERGY, 2015, 70 : 386 - 386
  • [50] Experiences of Double-Blind, Placebo-Controlled Food Challenges (DBPCFC): a qualitative analysis of mothers' experiences
    Strinnholm, Asa
    Brulin, Christine
    Lindh, Viveca
    JOURNAL OF CHILD HEALTH CARE, 2010, 14 (02) : 179 - 188